Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$12.54 - $46.93 $1.33 Million - $4.97 Million
-105,885 Reduced 4.56%
2,215,385 $36 Million
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $15.7 Million - $23.1 Million
274,000 Added 13.38%
2,321,270 $168 Million
Q2 2021

Aug 16, 2021

SELL
$47.86 - $83.95 $3.9 Million - $6.84 Million
-81,500 Reduced 3.83%
2,047,270 $172 Million
Q1 2021

May 13, 2021

BUY
$44.38 - $63.97 $15.5 Million - $22.4 Million
350,000 Added 19.68%
2,128,770 $103 Million
Q4 2020

May 18, 2021

BUY
$32.94 - $47.15 $58.6 Million - $83.9 Million
1,778,770 New
1,778,770 $83.9 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $87.3M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Cederberg Capital LTD Portfolio

Follow Cederberg Capital LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cederberg Capital LTD, based on Form 13F filings with the SEC.

News

Stay updated on Cederberg Capital LTD with notifications on news.